SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Original HTML

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Sept. 8, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: March 9, 2026 to June 24, 2026

DEADLINE: October 5, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ARS knew or recklessly disregarded the risk of timeline problems related to CVS Caremark's addition of neffy to its formulary. The Company's guidance on the timeline for insurance coverage for neffy may shift considerably, impacting its commercialization. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about ARS, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

SOURCE Schall, Brown & Schwartz LLP

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rejected
Dedupe hash
31d079b5bd52a3235be47d4f8b53236a
Press Eligible
No
Press Eligible Reason
[Retro-Cleanup] legal spam
Source Name
Unknown Company
Original Summary

<p>LOS ANGELES, Sept. 8, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the...</p>

Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "ARS Pharmaceuticals Faces Securities Fraud Class Action Over Neffy Timeline", "body_html": "<p><strong>Los Angeles -- [CURRENT_DATE] --</strong> Schall, Brown & Schwartz LLP has filed a securities class action against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), alleging the company misled investors about the commercialization timeline for its epinephrine nasal spray, neffy.</p><h5>Class period spans March 9 to June 24, 2026, covering key formulary disclosures</h5><p>The lawsuit targets shareholders who purchased ARS Pharmaceuticals stock between March 9, 2026 and June 24, 2026. Lead plaintiff applications must be filed by October 5, 2026.</p><h5>Complaint alleges ARS concealed risks tied to CVS Caremark formulary addition</h5><p>According to the complaint, ARS knew or recklessly disregarded the risk that CVS Caremark's addition of neffy to its formulary faced timeline problems. The suit claims the company's public guidance on insurance coverage timing could shift considerably, directly affecting neffy's path to market.</p><h5>Investors allege false statements inflated stock value before market correction</h5><p>The filing asserts that ARS Pharmaceuticals made false and materially misleading statements throughout the class period regarding the commercialization outlook for neffy. Shareholders suffered losses once the market learned the true status of the CVS Caremark formulary timeline, according to the complaint filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.</p><h5>Class has not yet been certified, leaving shareholders unrepresented for now</h5><p>Schall, Brown & Schwartz LLP notes that the class has not been certified, meaning affected shareholders are not currently represented by counsel. Investors may remain absent class members if they take no action, though the firm is soliciting lead plaintiff candidates ahead of the October 5, 2026 deadline.</p>", "meta_description": "ARS Pharmaceuticals faces a securities class action over alleged misleading statements on neffy's CVS Caremark formulary timeline, with an October 5, 2026 deadline.", "seo_keywords": "ARS Pharmaceuticals, SPRY, neffy, securities class action, CVS Caremark, shareholder lawsuit, Schall Brown Schwartz, biopharmaceuticals litigation", "companies": ["ARS Pharmaceuticals", "Schall, Brown & Schwartz LLP", "CVS Caremark"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["legal_action", "financial_disclosure"], "products": ["neffy"], "themes": ["regulatory_compliance", "investor_relations", "market_risk"], "events": [], "cta_text": "Shareholders who purchased SPRY stock during the class period may contact the firm regarding lead plaintiff appointment.", "learn_more": "https://www.schallfirm.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}